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ABSTRACT: Zika virus (ZIKV) is a mosquito-borne flavivirus
that has been associated with neuropathology in fetuses and
adults, imposing a serious health concern. Therefore, the
development of a vaccine is a global health priority. Notably,
neutralization tests have a significant value for vaccine develop-
ment and virus diagnosis. The cytopathic effect (CPE)-based
neutralization test (Nt-CPE) is a common neutralization method
for ZIKV. However, this method has some drawbacks, such as
being time-consuming and labor-intensive and having low-
throughput, which precludes its application in the detection of
large numbers of specimens. To improve this problem, we
developed a neutralization test based on an enzyme-linked
immunospot assay (Nt-ELISPOT) for ZIKV and performed the
assay in a 96-well format. A monoclonal antibody (mAb), 11C11, with high affinity and reactivity to ZIKV was used to detect
ZIKV-infected cells. To optimize this method, the infectious dose of ZIKV was set at a multiplicity of infection (MOI) of
0.0625, and a detection experiment was performed after incubating for 24 h. As a result, under these conditions, the Nt-
ELISPOT had good consistency with the traditional Nt-CPE to measure neutralizing titers of sera and neutralizing antibodies.
Additionally, three neutralizing antibodies against ZIKV were screened by this method. Overall, we successfully developed an
efficient neutralization test for ZIKV that is high-throughput and rapid. This Nt-ELISPOT can potentially be applied to
detecting neutralizing titers of large numbers of specimens in vaccine evaluation and neutralizing antibody screening for ZIKV.
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Zika virus (ZIKV), an arbovirus belonging to the Flavivirusgenus, is a member of the Flaviviridae family. It is closely
related to other important arboviruses, such as dengue virus
(DENV), yellow fever virus (YFV), West Nile virus (WNV),
Japanese encephalitis virus (JEV), and tick-borne encephalitis
virus (TBEV).1 ZIKV was first discovered in the serum of a
rhesus macaque in Uganda in 1947.2 Nonetheless, the first
ZIKV outbreak occurred on Yap Island in 2007.3,4 Since then,
larger epidemics of ZIKV occurred in French Polynesia in
2013−2014 and in Brazil in 2014−2015.5 In 2016−2017,
ZIKV spread to the Americas where it has become widely
disseminated and caused a major epidemic.6 Increasing
evidence indicates the association between ZIKV infection
and congenital birth defects and Guillain-Barre ́ syndrome
(GBS) in adults.7−9 In addition, ZIKV could be transmitted
through Aedes sp. mosquitoes, similar to most other flavivirus
members, but also by vertical and sexual routes.9−11 These
unexpected and unique prosperities urgently necessitate a safe
and effective vaccine. However, no licensed preventative
vaccine or therapeutic drug against ZIKV has been approved.
Humoral immunity response plays a crucial role in the
protective mechanism of vaccines. Moreover, the level of
neutralizing antibody is considered a significant indicator for
epidemiological surveys of ZIKV.12,13 Therefore, a neutraliza-
tion assay for ZIKV should be established to promote vaccine
development and virus diagnosis. The cytopathic effect (CPE)-
based neutralization test (Nt-CPE) has achieved wide use in
determining neutralizing titers of serum or antibodies against
flaviviruses;14,15 however, it is not suitable for the detection of
large numbers of specimens because of its time-consuming,
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low-throughput, and labor-intensive properties. Therefore,
there is an urgent need to develop an efficient neutralization
test for ZIKV.
Recently, researchers have tried to develop a high-
throughput and rapid neutralization test for ZIKV. In 2017,
a rapid ZIKV diagnostic assay (with a turnaround time within
48 h) was reported by Shan et al.16 However, the luciferase
viruses utilized to quantify the neutralizing antibody in their
method could not represent the clinical virus strain completely.
The enzyme-linked immunospot assay (ELISPOT) has been
widely used and demonstrated to be a highly sensitive,
objective, and high-throughput immunological method for
detecting neutralizing antibodies against many kinds of viruses,
including DENV, which is also a flavivirus;14,17,18 enterovirus
71 (EV71);19 coxsackievirus A16 (CVA16);20 coxsackievirus
A10 (CVA10);21 coxsackievirus B3 (CVB3);22 rotavirus;23
HSV-1.24 However, whether this assay can be applied to ZIKV
remains unknown. In the present study, a high-throughput and
rapid neutralization test based on an ELISPOT assay (Nt-
ELISPOT) for ZIKV was established and showed good
consistency with the Nt-CPE. Moreover, three neutralizing
antibodies against ZIKV were successfully identified by this
method.
■ MATERIALS AND METHODS
Cells and Viruses. African green monkey kidney (Vero)
cells (American Type Culture Collection, ATCC) were
maintained in high-glucose Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS,
GIBCO), 100 U/mL penicillin, 100 μg/mL streptomycin, and
2 mM L-glutamine at 37 °C with 5% CO2.
The three ZIKV strains used in this study were PRVABC59
(GenBank accession No. KU501215, belonging to the Asian
lineage ZIKV, isolated from a serum sample of a ZIKV infected
patient in 2015, obtained from ATCC),25 SZ-WIV01
(GenBank accession No. KU963796, belonging to the Asian
lineage ZIKV, isolated from a serum sample of a 38-year-old
Chinese male patient in 2016, kindly provided by the Academy
of Military Medical Sciences of China),26 and MR766
(GenBank accession No. LC002520, belonging to the African
lineage ZIKV, isolated from a sentinel monkey in Uganda in
1947, obtained from ATCC).27 Viral propagation was
performed in Vero cells.28 For the estimation of viral infectivity
titers, virus samples were serially diluted 10-fold (10 dilutions,
eight wells for each dilution) and then added to Vero cells
(5000 cells/well) preseeded into 96-well plates. After
incubating for 5−7 days, cytopathic effects (CPEs) were
observed and the 50% tissue culture infectious dose (TCID50)
of the virus stocks was determined by the Reed-Muench
method.29 For the calculation of multiplicity of infection
(MOI), the virus titers were converted from TCID50 to plaque
forming unit (PFU) by multiplying by 0.69, followed by
dividing by the number of cells.
Monoclonal Antibody Production. Monoclonal anti-
bodies (mAbs) against ZIKV were prepared using hybridoma
technology.30 Briefly, six-week-old female BALB/c mice used
in this study were purchased from Slac Laboratory Animal Co.,
Ltd., Shanghai, China, and subcutaneously immunized with the
PRVABC59 strain of ZIKV (106 TCID50/mouse), which was
emulsified in an equal volume of Freund’s adjuvant (Sigma-
Aldrich), three times at 2-week intervals. Then, the virus was
infected directly into the spleen of the immunized mice. Three
days later, spleen cells were separated and fused with SP2/0
myeloma cells (University of Pavia, Lombardy, Italy) according
to hybridoma technology.30 Afterward, hybridoma super-
natants were screened by an enzyme-linked immunosorbent
assay (ELISA) against PRVABC59, and the positive clones
were further amplified in the abdominal cavity of a mouse.
Finally, mAbs were obtained from mouse ascetic fluid and
purified by protein A chromatography (GE Healthcare). All
the mAbs were conjugated with horseradish peroxidase (HRP)
using the NaIO4 oxidation method,
31 mixed with an equal
volume of glycerine, and stored at −20 °C.
Western Blotting Assay. Vero cells seeded in 6-well plates
were infected with viruses at an MOI of 0.1 or mock infected
as a control. Forty-eight hours later, cell lysates were treated
with two kinds of loading buffers: one was in a reducing
condition with the presence of β-mercaptoethanol (β-ME),
and the other was in a nonreducing condition without β-ME.
Specifically, the samples with β-ME were heated for 10 min at
100 °C. Then, all the samples were loaded onto a 12% SDS-
PAGE gel and transferred to a nitrocellulose membrane
(Whatman). Subsequently, the proteins were sequentially
incubated with an anti-ZIKV mAb (produced in our lab)
and an anti-GAPDH mAb (#60004-1-Ig, Proteintech, USA) as
the primary antibody, an HRP-conjugated goat-antimouse
(GAM-HRP) as the secondary antibody (Sigma-Aldrich, St.
Louis, MO, USA), and Pierce ECL Western blotting Substrate
(#34095, ThermoFisher Scientific, USA) according to the
manufacturer’s recommendation.
Immunofluorescence Assay. Vero cells were seeded in
12-well plates containing a 1 cm2 circular coverslip in each well
and then infected with viruses at an MOI of 0.1. At 24 h
postinfection, cells on the coverslips were fixed with 4%
paraformaldehyde (PFA) in the dark for 30 min, permeabilized
with 0.1% Triton X-100 in phosphate-buffered saline (PBS) for
10 min, and blocked with 2% bovine serum albumin (BSA) (in
PBS) for 30 min. The cells were then incubated with the anti-
ZIKV mAb 11C11 (generated in our laboratory) at 37 °C for 1
h and washed three times with PBS before incubation with
Alexa Fluor 488-conjugated secondary antibodies (antimouse
IgG, #A21202, Invitrogen) in 2% BSA at 37 °C for 30 min.
Finally, after 5 min of DAPI (#D1306, Invitrogen) nuclear
staining, cells on the coverslips were imaged with a
fluorescence microscope (Zeiss, Germany).
Nt-CPE. Vero cells were seeded with 5 × 103 cells per well
into 96-well plates at least 6 h prior to infection. The test
samples were serially diluted 2-fold from 1:16 to 1:8192 with
DMEM (four wells were used for each dilution). Then, the
serial dilutions of test samples were mixed with an equal
volume of the PRVABC59 strain of ZIKV (200 PFU) and
incubated for 1 h at 35 °C. We chose the low temperature (35
°C) for this experiment to slow the growth of Vero cells so as
to have sufficient incubation time to observe the CPE caused
by ZIKV infection. The mixtures were then added to the cell
plates. The CPE was then observed by microscopy after
incubation for 5 days at 35 °C and 5% CO2. The wells with
different dilutions of samples associated with and without CPE
were considered as negative and positive wells, respectively.
The neutralizing titers were read as the highest dilution that
completely inhibited CPE in >50% of the wells.
Positive and Negative Serum/mAb Samples. Positive
samples were defined as having an inhibitory effect on the CPE
of ZIKV infection. In contrast, negative samples were defined
as no inhibition effect on the CPE of ZIKV. Positive and
negative serum samples were collected from BALB/c mice that
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were immunized and not immunized with the PRVABC59
strain, respectively. The positive mAb sample used in this study
was screened by the Nt-CPE test against PRVABC59, and the
negative mAb was an unrelated mAb that had no inhibitiory
effect on the CPE of ZIKV. All the sera/mAbs were stored at
−20 °C, and the serum samples were inactivated at 56 °C for
30 min before testing neutralizing titers.
Nt-ELISPOT. Vero cells were seeded at 2 × 104 cells per
well into 96-well plates at least 6 h prior to infection. The test
samples were serially diluted 2-fold from 1:16 to 1:8192 with
DMEM. Then, the serial dilutions of test samples were mixed
with an equal volume of virus in a total volume of 0.1 mL.
After incubation for 1 h at 35 °C (to be consistent with the
experiments of Nt-CPE, the cells were incubated at 35 °C), the
mixtures were added to the cell plates. Specifically, the last two
columns of the 96-well plate were set as the virus control
column and the cell control column. The virus control wells
were infected with the same infectious dose of virus as that for
the test wells, and the cell control wells received an equal
volume of DMEM. The plates were then incubated at 35 °C
for 24 h. After incubation, the cells infected with ZIKV were
detected by an ELISPOT assay. Briefly, the cells were fixed
with 1% formaldehyde in PBS for 1 h and permeated with 1%
Triton X-100 in PBS for 30 min. The detection antibody used
for the Nt-ELISPOT, which was conjugated to HRP, was
diluted with 2% gelatin and 5% casein (in PBS) and then
added into the plates. After incubation for 30 min at 37 °C, the
plates were washed five times with PBST (0.05% Tween 20 in
PBS). Then, a tetramethylbenzidine (TMB) substrate solution
(Sigma-Aldrich, St. Louis, MO, USA) was added to the plates
and incubated for 10 min. After staining, the plates were patted
dry, followed by scanning with an ImmunoSpot 5S UV
Analyzer (Cellular Technology Limited, Shaker Heights, OH,
USA) using the blue color system, and counted with
ImmunoSpot professional analysis software (version 5.0;
Cellular Technology Limited). The counting parameters
were set as follows: the spot size was set between 0.0001
(Min) and 9.6296 (Max) mm2, the sensitivity was set to an
arbitrary value between 180 and 200, and the background
balance and the diffuse spot process was 0. All samples were
tested in quadruplicate. The inhibition rate of the test samples
was calculated using the following equation: P (%) = [1 −
(Ntest − Ncell control)/(Nvirus control − Ncell control)] × 100%. In this
equation, P (%) is the inhibition rate of the test sample, and
Ntest, Nvirus control, and Ncell control are the average number of
spots in the test well, in the cell control wells, and in the virus
control wells, respectively. The neutralizing titer of the test
sample was read as the highest dilution that completely
inhibited >50% of the spots.
Statistics. Statistical analyses of experimental data were
performed using GraphPad Prism software version 7.04
(GraphPad Prism software Inc., La Jolla, CA). The 50%
inhibitory concentration (IC50) of each mAb was defined as
the concentration when P (%) equals 50%. The IC50 was
estimated by nonlinear, dose−response regression analysis.
Data are given as the mean ± standard deviation (SD), as
Figure 1. Evaluation of the reactivity of the detection antibody 11C11 against ZIKV. Vero cells infected with three strains of ZIKV (PRVABC59,
SZ-WIV01, and MR766) were used in this study. (a) Western blotting analysis. ZIKV-infected cells and mock-infected cells were suspended in lysis
buffer with or without the presence of β-mercaptoethanol (β-ME) and subjected to 12% SDS-PAGE. The proteins were probed with the mAb
11C11 and then with a horseradish peroxidase (HRP)-conjugated goat antimouse secondary antibody. (b) Immunofluorescence analysis. ZIKV-
infected and mock-infected Vero cells were fixed and incubated with the mAb 11C11 and an Alexa Fluor 488-conjugated antimouse secondary
antibody (green). The nuclei were stained with DAPI (blue). Scale bar = 10 μm. (c) ELISPOT assay. PRVABC59-infected (MOI = 0.0625), SZ-
WIV01 (MOI = 0.1), MR766-infected (MOI = 0.07), and mock-infected Vero cells were fixed and incubated with the HRP-conjugated mAb
11C11. ZIKV-infected cells were visualized as blue spots after adding TMB substrate.
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indicated. Comparisons between two groups were performed
using unpaired Student’s t-tests. A p value of <0.05 was
considered statistically significant.
■ RESULT
Characterization of a Specific Monoclonal Antibody,
11C11, against ZIKV. To select an mAb with high affinity for
ZIKV, a group of mAbs against ZIKV were produced in our
laboratory from mice that were immunized with the
PRVABC59 ZIKV strain. By performing Western blot and
immunofluorescence analysis, the mAb 11C11, which ex-
hibited relatively good reactivity with ZIKV-infected (including
the Asian lineage ZIKV strains PRVABC59 and SZ-WIV01 and
the African lineage ZIKV strain MR766) Vero cells but not
with uninfected cells (Figure 1a,b), was selected as the
detection antibody for an ELISPOT test. It should be noted
that the mAb 11C11 did not react with the samples suspended
by reducing loading buffer in the Western blot assay, indicating
that 11C11 recognized a conformational region that involves
disulfide bonds of a ZIKV protein (Figure 1a). Meanwhile, this
recognized region was conserved in both Asian and African
lineage ZIKV strains (Figure 1a,b). Then, the mAb 11C11 was
further conjugated with HRP (1 mg/mL, 1:1000 dilution rate)
to test in the ELISPOT method for recognition of ZIKV-
infected Vero cells. As shown in Figure 1c, only the infected
cells were visualized as blue spots after adding TMB substrate.
The data above indicated that the detection mAb 11C11 could
react with both Asian and African lineage ZIKV strains with a
low background and showed good affinity and reactivity.
Determination of the Optimal Infectious Dose and
Cultivation Periods for the Nt-ELISPOT. The next goal was
to establish an effective neutralization test for ZIKV. Since the
infectious dose and cultivation periods have a considerable
impact on the infection kinetics, we then optimized these
factors to develop the Nt-ELISPOT. Because PRVABC59 is a
representative virus strain that belongs to the Asian lineage and
was isolated from a ZIKV-infected patient in the outbreak in
2015 in Brazil, we selected the PRVABC59 strain of ZIKV for
further optimization.
First, an infectious dose between 0.25 and 0.0078125 MOI
per well with serial 2-fold dilutions was used to infect Vero
cells in this study. Then, during incubation, spot numbers were
read and counted every 4 h by the ImmunoSpot analyzer over
a period of 40 h. As shown in Figure 2, spots in the plate wells
with an MOI = 0.25 or 0.125 could be detected at the
incubation time of 16 h and peaked after cultivating for 20 h;
however, the spot numbers could not be counted accurately
because the spots connected after an incubation time longer
than 28 h (so these data were not collected). When the
infectious dose was 0.0078125 to 0.0625 MOI, the growth
curves of the spot numbers were similar and “S”-shaped; the
spot numbers increased with increasing infectious dose and
incubation time and then decreased after cultivation for 32 h
due to separation of the heavily infected cells from the culture
dish. In a previous study, we found that the Nt-ELISPOT for
coxsackievirus B3 (CVB3) and coxsackievirus A16 (CVA16)
obeys the “percentage law”; that is, when the spots are counted
during the log phase or the first half of the stationary phase on
the growth curve of the spots, the infectious dose of the Nt-
ELISPOT has nearly no influence on the neutralizing titers of
the sera.20,22 Therefore, to shorten the incubation time, we set
the infection time to 24 h. At this time point, the higher the
infectious dose used, the more spot numbers were counted and
the higher sensitivity was obtained. To balance the relationship
between spot numbers and consumption of the virus, an MOI
of 0.0625 was selected as the infectious dose for the Nt-
ELISPOT. When we chose the infection dose of 0.0625 MOI
per well and detection at 24 h postinfection, the number of
spots in the infected wells was approximately 1000 but that in
the mock-infected group or the UV-inactivated ZIKV group
was fewer than 50 (Figure 2), which showed a high reactivity
to ZIKV; thus, this infectious dose and infection time were
used for the further Nt-ELISPOT. The resulting Nt-ELISPOT
protocol for ZIKV is diagrammed in Figure 3. Our approach
resulted in a neutralization test that could be completed within
48 h and allowed a 96-well format.
Comparison of the Nt-CPE with the Nt-ELISPOT. To
examine the feasibility of the ELISPOT assay in detecting the
neutralizing titer of sera and antibody, it was compared with
the traditional CPE neutralization test. Four samples (one
PRVABC59-immunized mouse serum, one nonimmunized
mouse serum, one neutralizing antibody-positive antibody, and
one neutralizing antibody-negative antibody) with neutralizing
titers of 512, <16, 1024, and <16 for ZIKV, respectively,
determined by the Nt-CPE test were used. Furthermore,
multiple test samples with decreasing neutralizing capacities
were obtained by serially diluting the four samples in 2-fold
dilutions and detected by both the Nt-CPE and Nt-ELISPOT.
As shown in Figure 4a,c, for the positive samples, the
neutralizing titers tested by the Nt-ELISPOT assay decreased
2-fold with the increasing dilution of the samples and had no
statistical difference with those determined by the Nt-CPE test.
In addition, for the negative samples, the neutralizing titers of
the antibody-negative serum or mAb were both <16, as
detected by both the Nt-CPE and Nt-ELISPOT (Figure 4b,d).
Therefore, these results revealed that the Nt-ELISPOT had
good consistency with the Nt-CPE test, which could
potentially replace the traditional neutralization test to measure
neutralizing titers against ZIKV in both sera and antibodies.
Nt-ELISPOT Could Be Used for the Screening of
Neutralizing Antibodies against ZIKV. Neutralizing anti-
bodies are a useful tool for treating disease and studying the
pathogenesis of ZIKV.32,33 Because the Nt-ELISPOT could
test the neutralizing titer quickly and with high-throughput, we
tried to apply this method to obtain neutralizing antibodies
against ZIKV. In detail, the splenocytes from PRVABC59-
Figure 2. Determination of the optimal infectious dose and
cultivation periods for the Nt-ELISPOT. Vero cells (2 × 104 cells/
well) preseeded onto 96-well plates were infected with the
PRVABC59 strain of ZIKV at an MOI of 0.25 to 0.0078125 per
well. An ELISPOT assay was performed to detect the number of spots
every 4 h over a period of 40 h. The mock-infected wells and UV-
inactivated ZIKV wells were regarded as the negative controls. Each of
the dilutions was performed in quadruplicate. The error bars indicate
the mean ± SD for the number of spots.
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immunized BALB/c mice were fused with sp2/0 cells, and
then, the hybridoma supernatant was tested by the Nt-
ELISPOT. Eventually, three antibodies were obtained after
screening and cloning for five rounds. The results indicated
that the mAbs 7F3, 12F12, and 8A6 could effectively inhibit
the infection of Vero cells by ZIKV, but the number of spots in
the wells of cells treated with an unrelated antibody, which was
used in Figure 4d, and PBS-treated cells was >1000 (Figure
5a). To further detect the neutralizing ability of the mAbs, 7F3,
12F12, and 8A6 were serially diluted in a 2-fold ration (the
initial concentration was 1 mg/mL) and then tested by the Nt-
ELISPOT. As shown in Figure 5b, the IC50 values of the mAbs
7F3, 12F12, and 8A6 were 3.55, 1.33, and 0.57 μg/mL,
respectively. Therefore, we obtained three neutralizing mAbs
against ZIKV as demonstrated by the Nt-ELISPOT.
■ DISCUSSION
The neutralizing titer of a neutralizing antibody is the key
indicator to evaluate the immunogenicity of candidate
vaccines.33 Therefore, a rapid and high-throughput neutraliza-
tion test for ZIKV is urgently needed, which is significant for
promoting the development of vaccines. However, currently,
the Nt-CPE assay, the classical neutralization method for
flaviviruses,14,15 is time-consuming (with 5−7 days) and labor-
intensive and has low-throughput, so it can hardly meet the
demands of the detection of large numbers of specimens in
vaccine development or serosurvey. Researchers in this field
have tried to overcome this limitation. To our knowledge, two
novel neutralization assays for ZIKV have been reported to
date. One was based on an ELISA reported in 2016,34 but the
correlation with the traditional neutralization method was
unknown, and the whole experimental period needed 4 days,
which is nearly as long as the Nt-CPE. The other assay was
developed systematically by Shan et al. in 2017,16 which was
rapid and sensitive, but it relied on the virus containing a
reporter gene that could not represent the clinical virus strain
completely.
In the current study, a neutralization test based on an
ELISPOT assay was first developed for ZIKV systematically.
ELISPOT technology has been developed for many years.
However, it was used initially for analysis of antibody-secreting
cells but seldom for humoral immunity assessment.35 Later, it
was applied for detecting cytokines, employing high-affinity
capture and detection antibodies.36 In the past few years, some
studies have used it for the detection of neutralizing antibodies
against many kinds of viruses (such as EV71, CVA16, CVA10,
DENV, HCMV, and so on) due to its highly sensitive,
objective, and high-throughput properties.18−24 Here, to
develop the Nt-ELISPOT for ZIKV, several factors were
optimized. First, although the Asian lineage of the ZIKV strain
was the main lineage in recent outbreaks, the African lineage
has also shown some serious clinical signs in animals and
human reconstituted tissues.28,37,38 Therefore, to enhance the
applicability of this method, the mAb 11C11, which could
Figure 3. Flow diagram of the ELISPOT assay for the determination of neutralizing titers of the specimens. This assay was performed in a 96-well
plate. First, Vero cells (2 × 104 cells/well) were seeded at least 6 h prior to infection. Then, the serial dilutions of the test samples were mixed with
an equal volume of virus and incubated for 1 h at 35 °C. The mixtures were added to the cell plates, with the last two columns set as the virus
control wells and the cell control wells. After incubation at 35 °C for 24 h, the ELISPOT assay was performed for the detection of neutralizing titers
of specimens. The infected wells were visualized as blue spots after adding the TMB substrates. The number of spots was counted by an
ImmunoSpot analyzer and recorded in the upper right corner of the image. The neutralizing titer of the test sample was read as the highest dilution
that completely inhibited >50% of the spots.
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react with both Asian and African ZIKV strains with low
background and good affinity, was selected as the detection
antibody. Then, to shorten the infectious time and obtain clear
spots, the optimal infectious dose and incubation time were set
as 0.0625 MOI/well and 24 h, respectively. In addition, to
verify the feasibility of the ELISPOT assay for the detection of
neutralizing titers, we compared the Nt-ELISPOT with Nt-
CPE and found that there was a good consistency between
them. Overall, the successful construction of the Nt-ELISPOT
relied on only a sensitive cell line, a high-affinity antibody, and
an automated ELISPOT analyzer. As for the ELISPOT
analyzer, it is easy to operate the experiments and capture
the ELISPOT images of one 96-well plate. The experiment
needs about 5 min/plate. After capturing the images, the
number of spots with different sizes can be counted using the
ImmunoSpot professional analysis software with the parameter
settings (such as sensitivity, background balance, diffuse spot
process, and spot separation). Therefore, Nt-ELISPOT could
also be further expanded to the application of other viruses.
Indeed, studies from other groups have applied an mAb
against ZIKV, such as mAb 4G2 (pan-DENV anti-E
protein)39,40 and a humanized anti-WNV E60,41 to examine
the infected cells in the neutralization tests. First, these
antibodies have been used to visualize the ZIKV-infected cell
by incubating with HRP-conjugated secondary antibody. In
addition, these antibodies were also used for neutralization
tests in which a 96-well plate was used for a high-throughput
examination. However, the Nt-ELISPOT developed in our
study has advantages. First, the antibody used for Nt-ELISPOT
had been directly conjugated with HRP, so staining spots need
to incubate with only one antibody, which was more
convenient and time-saving than the indirect method. Second,
the growth curves of the spot numbers with increasing
infectious dose and cultivation periods were optimized for the
Nt-ELISPOT, so the whole time for detection was less than 48
h. More importantly, the Nt-ELISPOT has good consistency
with the traditional Nt-CPE in measuring the neutralizing titers
of sera and neutralizing antibodies. Therefore, the neutraliza-
tion test based on the ELISPOT assay was developed
systematically in our study.
The Nt-ELISPOT developed in this study would have a
wide application. In addition to evaluating the humoral
immune response induced by vaccines, here, we successfully
screened three neutralizing antibodies against ZIKV through
the use of this method, and the protective efficacy of the mAbs
could be further evaluated in vivo to promote the study of
therapeutic antibodies for ZIKV. Furthermore, this assay could
also be used as an assistant tool for seroepidemiological surveys
and clinical diagnoses. However, due to serum from humans
who may suffer from ZIKV and/or DENV, the background of
human serum may be more complex than that of mice serum.
Moreover, anti-ZIKV antibodies are highly cross-reactive with
other viruses within the same family, so it was challenging to
diagnose the cross-reactivity of the serum from ZIKV patients
with other flaviviruses, especially DENV.42 Therefore, in the
follow-up study, the human serum samples, especially from
ZIKV and DENV infected individuals, needed to be detected
by the Nt-ELISPOT to evaluate its clinical relevance. Besides,
the reactivity of detection antibody 11C11 with other virus
strains also needs to be tested in a further study. If the mAb
Figure 4. Comparison of the Nt-CPE and the Nt-ELISPOT. Four samples, one ZIKV-immunized mouse serum (a), one nonimmunized mouse
serum (b), one neutralizing antibody-positive mAb (c), and one neutralizing antibody-negative mAb (d), selected by the Nt-CPE with the
neutralizing titers 512, <16, 1024, and <16, respectively, were serially diluted 2-fold. Each diluted sample was then detected by both the Nt-CPE
and Nt-ELISPOT. The neutralizing titer determined by the Nt-CPE and Nt-ELISPOT was read as the highest dilution that completely inhibited
CPE in >50% of the wells and completely inhibited >50% of the spots, respectively. All samples were tested in quadruplicate. The error bars
indicate the mean ± SD for the neutralizing titer. “N.S.” means no significant difference.
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11C11 was specific to ZIKV but not to other common
flaviviruses, such as DENV, WNV, and YFV, it might be a
useful tool to distinguish ZIKV from other flaviviruses. If it
could also react with other flaviviruses, the mAb 11C11 could
also be applied as the detection antibody to detect the
neutralizing titers against them by Nt-ELISPOT; then, the
flavivirus prevalence could be preliminarily understood by the
comprehensive analysis of the neutralizing titers for both ZIKV
and DENV or other flaviviruses.
In summary, we have successfully developed a neutralization
test against ZIKV based on an ELISPOT assay. The Nt-
ELISPOT method is high-throughput, objective, and low cost,
and the whole detection time was <48 h. Moreover, the
technique has a good relationship with the traditional Nt-CPE
to measure neutralizing titers of sera or antibodies. Therefore,
the Nt-ELISPOT for ZIKV can potentially be applied to
detecting neutralizing titers of large numbers of specimens in
vaccine evaluation and neutralizing antibody screening of
ZIKV.
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